Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD® and VANTAFLU® in South Korean Subjects Aged ≥65 Years
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Backgroud: Influenza vaccination is recommended for adults aged ≥65 years as they are at high risk of significant morbidity and mortality. This open-label, multicenter, post-marketing surveillance study assessed the safety of the MF59-adjuvanted trivalent inactivated subunit influenza vaccine, which is marketed as FLUAD® and VANTAFLU®, in South Korean subjects aged ≥65 years. Materials and Methods: Solicited local and systemic adverse events (AEs) were collected from day 1 to 4 of the study. All unsolicited AEs and serious AEs (SAEs) were recorded from day 1 until study termination (day 29). Results: Of the 770 subjects enrolled (FLUAD®, n = 389; VANTAFLU®, n = 381), 39% overall experienced any solicited AE. Local AEs were reported by 33% of subjects overall; with the most common events being injection-site pain (30%) and tenderness (27%). Systemic AEs were reported by 19% of subjects overall with the most common events being myalgia (11%) and fatigue (8%). Conclusion: These results show that the MF59-adjuvanted influenza vaccine known as FLUAD® or VANTAFLU® had acceptable safety profiles in older adults (aged ≥65 years) in South Korea.
Abstract
Backgroud: Influenza vaccination is recommended for adults aged ≥65 years as they are at high risk of significant morbidity and mortality. This open-label, multicenter, post-marketing surveillance study assessed the safety of the MF59-adjuvanted trivalent inactivated subunit influenza vaccine, which is marketed as FLUAD® and VANTAFLU®, in South Korean subjects aged ≥65 years. Materials and Methods: Solicited local and systemic adverse events (AEs) were collected from day 1 to 4 of the study. All unsolicited AEs and serious AEs (SAEs) were recorded from day 1 until study termination (day 29). Results: Of the 770 subjects enrolled (FLUAD®, n = 389; VANTAFLU®, n = 381), 39% overall experienced any solicited AE. Local AEs were reported by 33% of subjects overall; with the most common events being injection-site pain (30%) and tenderness (27%). Systemic AEs were reported by 19% of subjects overall with the most common events being myalgia (11%) and fatigue (8%). Conclusion: These results show that the MF59-adjuvanted influenza vaccine known as FLUAD® or VANTAFLU® had acceptable safety profiles in older adults (aged ≥65 years) in South Korea.
참고문헌 (28)
- "Influenza (Seasonal). Fact sheet 211"[URL]
- McElhaney JE, "The unmet need in the elderly: designing new influenza vaccines for older adults", Vaccine, 23(Suppl 1), pp.S10~S25 (2005)
- McElhaney JE, "Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines", Aging Health, 4, pp.603~613 (2008)
- Monto AS, "Influenza control in the 21st century: Optimizing protection of older adults", Vaccine, 27, pp.5043~5053 (2009)
- Cromer D, "The burden of influenza in England by age and clinical risk group: a statistical analysis to inform vaccine policy", J Infect, 68, pp.363~371 (2014)
- Thompson WW, "Mortality associated with influenza and respiratory syncytial virus in the United States", JAMA, 289, pp.179~186 (2003)
- Theodore F. Tsai, "Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults", Infection and Chemotherapy, 45(2), pp.159~174 (2013), 대한감염학회
- Lambert ND, "Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach", Expert Rev Vaccines, 11, pp.985~994 (2012)
- Loubet P, "Seasonal influenza vaccination of high-risk adults", Expert Rev Vaccines, 15, pp.1507~1518 (2016)
- Nichol KL, "Effectiveness of influenza vaccine in the community-dwelling elderly", N Engl J Med, 357, pp.1373~1381 (2007)
- Gavazzi G, "Ageing and infection", Lancet Infect Dis, 2, pp.659~666 (2002)
- Gruver AL, "Immunosenescence of ageing", J Pathol, 211, pp.144~156 (2007)
- McElhaney JE, "Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults", Expert Rev Vaccines, 12, pp.759~766 (2013)
- Talbot HK, "Association between obesity and vulnerability and serologic response to influenza vaccination in older adults", Vaccine, 30, pp.3937~3943 (2012)
- "FDA approves first seasonal influenza vaccine containing an adjuvant" (2015)[URL]
- "US Package Insert" (2017)[URL]
- Pellegrini M, "MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database", Vaccine, 27, pp.6959~6965 (2009)
- Podda A, "The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine", Vaccine, 19, pp.2673~2680 (2001)
- Frey SE, "Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects", Vaccine, 32, pp.5027~5034 (2014)
- Banzhoff A, "A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis", Gerontology, 49, pp.177~184 (2003)
- Puig-Barberà J, "Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age", Vaccine, 23, pp.283~289 (2004)
- "Standard for re-examination of new drugs, etc. Notice 2010-94"[URL]
- De Donato S, "Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly", Vaccine, 17, pp.3094~3101 (1999)
- Minutello M, "Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons", Vaccine, 17, pp.99~104 (1999)
- Scheifele DW, "Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison", Hum Vaccin Immunother, 9, pp.2460~2473 (2013)
- Nichol KL, "Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly", N Engl J Med, 348, pp.1322~1332 (2003)
- Thompson WW, "Influenza-associated hospitalizations in the United States", JAMA, 292, pp.1333~1340 (2004)
- 윤재원, "The Korean Influenza National Immunization Program: History and Present Status", Infection and Chemotherapy, 49(4), pp.247~253 (2017), 대한감염학회